AI vs TEM: AI Stock Comparison

• “Because we derive substantially all of our revenue from subscriptions to our C3 AI Software and Center of Excellence support services, failure of Enterprise AI solutions in general and our…” — 10-K risk factor (filed 2026-06-24) · source
• “If we fail to respond to rapid technological changes, extend our C3 AI Software, or develop new features and functionality, our ability to remain competitive could be impaired.” — 10-K risk factor (filed 2026-06-24) · source

• “We have incurred significant losses since inception, we may continue to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain…” — 10-K risk factor (filed 2026-02-24) · source
• “If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or to achieve and then sustain profitability.” — 10-K risk factor (filed 2026-02-24) · source

C3.ai sells AI applications and a development platform. Its 10-K notes substantially all revenue comes from its AI software, so adoption pace is the whole story.

Tempus combines genomic testing with a large clinical data set and AI models for diagnostics and drug development.